TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
Study: NCT02305992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block with 0.2% Ropivicaine
Description: A stellate ganglion block is an injection of local anesthetic in the sympathetic nerve tissue of the neck. These nerves are a part of the sympathetic nervous system. The nerves are located on either side of the voice box, in the neck

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infiltration with 0.25% Bupivicaine
Description: Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
Study: NCT01715116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced ICD programming
Description: * VT monitor: \> 166/min~* fVT: \> 182/min; via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s); 3 x ATP (8 stimuli, 88%, scan 20 ms); shock 1-5: 35 J; redetection 30/40 intervals.~* VF: \> 250/min; via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s); 1 x ATP (8 stimuli, 88%) during charging; all shocks: 35 J; redetection 30/40 intervals~* SVT/VT discrimination is turned on, high rate time out is OFF~* SVT/VT discrimination single chamber: stability, wavelet; SVT upper rate limit: 222/min~* SVT/VT discrimination dual/triple chamber: P/R logic, wavelet; SVT upper rate limit: 222/min~* T wave-oversensing and lead noise discrimination is turned on in all devices.
Study: NCT02759133

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal wire
Description: Localization technique for breast surgery using metal wire

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radioactive Iodine Seed
Description: Localization technique for breast surgery using Radioactive Iodine Seed
Study: NCT01172392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon-alpha-2a
Description: 180 mcg / wk / SC from D0 to W48

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleotidic or Nucleosidic Treatment
Description: Analog treatment according to investigators practice
Study: NCT03903783

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: Patients with C3G antibiotic therapy will receive cefotaxime. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed.
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
Study: NCT01877694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auriclosene Solution 0.3%
Description: Ophthalmic solution dispensed as drops onto the eye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Auriclosene Vehicle
Description: Ophthalmic Vehicle solution dispensed as drops onto the eye
Study: NCT00914979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioSculpt
Description: The AngioSculpt Scoring Balloon Catheter is a standard balloon dilatation catheter with a scoring balloon near the distal tip
Study: NCT01672047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: 25（OH）D level \<12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month， \>116.75nmol/L stopped.
Study: NCT01897623

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound of aorta
Study: NCT03255291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Recording - Exercise
Description: Participants imagine themselves improving exercise
Study: NCT03502460

Intervention type: OTHER
Group type: OTHER
Intervention: Operating Room Fluid Administration Lung Ultrasound
Description: Use of lung ultrasound to limited fluid administration
Study: NCT03255291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Recording - Exercise
Description: Participants imagine themselves improving exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Recording - Exercise
Description: Participants imagine themselves improving exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: -Reminders to practice mental imagery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: -Reminders to practice mental imagery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: -Reminders to practice mental imagery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: -Reminders to practice mental imagery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: -Reminders to practice mental imagery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: -Reminders to practice mental imagery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Survey
Description: -Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Survey
Description: -Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Survey
Description: -Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Survey
Description: -Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Survey
Description: -Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Survey
Description: -Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.
Study: NCT05264090

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
Study: NCT05264090

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.
Study: NCT03903783

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Patients with C3G antibiotic therapy will receive ceftriaxone. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed.
Study: NCT03064750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvic floor exercises
Description: In preparation for surgery, patients receive individual information by a physiotherapist on pelvic floor anatomy and correct pelvic floor contraction. Patients are told to do the following pelvic floor exercises 3 times a day: 8-12 maximal contractions, hold contractions during 10 seconds, and 3 fast contractions after each long contraction. In addition exercise in groups with skilled physical therapists once a week during 12 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list
Description: patients wait as usual until surgery without special treatment.
Study: NCT05325060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetically navigated total knee arthroplasty
Description: The navigated group had surgery using the iNav portable EM navigation system (Zimmer GmbH, Winterthur, Switzerland and Medtronic, Minneapolis, MN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional total knee arthroplasty
Description: The conventional group received surgery using conventional instrumentation and jigs from the implant manufacturer (Zimmer Inc, Warsaw, IN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
Study: NCT02898805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
Study: NCT02898805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescribed Diet
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
Study: NCT02898805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescribed Diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LopiGLIK®

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Armolipid Plus
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
Study: NCT03069781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17β-estradiol
Description: 1mg/day for 3-days and 3mg/day for 7-days of Estrance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polycose
Description: 400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada)
Study: NCT00929591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT05264090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring
Description: The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Combined aerobic-resistance exercise
Description: Combined aerobic-resistance exercise (group 2) was scheduled twice weekly in the form of 60-minute workouts with a load intensity at the level of sub-maximum heart frequency (75-85% SFmax). The minimum time span between the workouts was 24 hours. The workout consisted of a 10-minute warm-up, 25 minutes of aerobic exercise (spinning bicycle or bicycle ergometer), 15 minutes of resistance exercise on gym machines (bench press, leg extension and pull down) with 40-50% 1-RM (one repetition maximum) intensity (3 series of 10 exercises), and a 10-minute cool-down (stretching of the main muscle groups).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The cardiovascular exercise
Description: The cardiovascular exercise (group 4) took the form of sixty-minute workouts scheduled two to three times weekly. The nature of the workouts was similar, combined aerobic-resistance exercise (a 10-minute warm-up, aerobic endurance on bicycle ergo meter for 25 minutes, resistance exercise on multifunctional gym machines for 15 minutes, and a 10-minute cool-down). The workout intensity was set at the level of the first ventilation threshold (VAT-1), corresponding to the following workout parameters: load (W) and heart rate (HR).19,20 The resistance exercise intensity was specified by the 1-RM (one repetition maximum) method. The maximum load lifted across the full range of motion for every exercise was used as the benchmark for the workload intensity specification, corresponding to 30 - 60% 1-RM.
Study: NCT00088634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: 80 mg AM dosing once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to 40mg lurasidone tablets
Study: NCT03220048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP-001

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Comparator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Study: NCT04676750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: yoga, meditation and psycho education
Study: NCT01395589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Children with moderate-to-severe asthma exacerbations and vitamin D levels \< 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months.
Study: NCT01338103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
Study: NCT03580993

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung ultrasound and Echocardiography used to derive parameters for prediction of successful SBT.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung ultrasound and Echocardiography used to derive parameters for prediction of successful SBT.
Study: NCT03985306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inforatio technique
Description: We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.~Inforatio technique is applied after standard care and wound assessment.